RecruitingNot ApplicableNCT06259890
Influence of Sodium Intake in spondyLoarthriTes
Sodium Intake in spondyLoarthriTes: Analysis of the Influence on the Activity of the Disease and the Therapeutic Response to Anti IL-17A Agents.
Sponsor
Centre Hospitalier Universitaire de Besancon
Enrollment
250 participants
Start Date
Jan 30, 2024
Study Type
INTERVENTIONAL
Conditions
Summary
The aim of the SALT study is to analyze the relationship between dietary sodium intake and disease activity in patients with axial spondyloarthritis (radiographic or non-radiographic) or psoriatic arthritis.
Eligibility
Min Age: 18 YearsMax Age: 80 Years
Inclusion Criteria2
- patients with axial spondyloarthritis (radiographic or non-radiographic) or psoriatic arthritis
- women who have been menopausal for at least 24 months, surgically sterilized, or, for women of childbearing potentiale, use an effective method of contraception (oral contraceptives, contraceptive injections, intrauterine devices, double-barrier method, contraceptive patches)
Exclusion Criteria4
- patient treated by cyclosporine, diuretics, angiotensin-converting enzyme inhibitors or angiotensin II receptor antagonists.
- current treatment with an anti-IL-17A agent (secukinumab or ixekizumab or bimekizumab or brodalumab) or with an anti-IL23 agent (ustekinumab, guselkumab, risankizumab or tildrakizumab) or previous treatment less than 6 months old.
- patients on systemic corticosteroids with corticosteroid therapy > 10 mg prednisone equivalent
- pregnant woman
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
OTHERmeasurement of salt intake
measurement of salt intake without intervention
Locations(4)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06259890
Related Trials
Evaluation of Sonelokimab in Patients With Active Psoriatic Arthritis and Anti-TNFα Inadequate Response
NCT06641089135 locations
A Study of Guselkumab in Participants With Psoriatic Arthritis (PsA) in a Real-World Setting
NCT0722082421 locations
A Study to Evaluate the Efficacy and Safety of Icotrokinra (JNJ-77242113) in Biologic-experienced Participants With Active Psoriatic Arthritis
NCT06807424214 locations
A Study to Evaluate the Efficacy and Safety of JNJ-88545223 for the Treatment of Participants With Active Psoriatic Arthritis
NCT0732187340 locations
A Study of Guselkumab Administered Subcutaneously in Treatment of Indian Participants With Psoriatic Arthritis (PsA)
NCT071410049 locations